Home LiteratureArticle Details
PMID: 15200821 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Multidrug-resistant tuberculosis in central Asia.

Emerging infectious diseases ·Vol. 10 ·No. 5 ·2004-05-00 ·Pages 865-72

Cox HS, Orozco JD, Male R, Ruesch-Gerdes S, Falzon D, Small I, Doshetov D, Kebede Y, Aziz M

Abstract

Multidrug-resistant tuberculosis (MDR-TB) has emerged as a major threat to TB control, particularly in the former Soviet Union. To determine levels of drug resistance within a directly observed treatment strategy (DOTS) program supported by Médecins Sans Frontières in two regions in Uzbekistan and Turkmenistan, Central Asia, we conducted a cross-sectional survey of smear-positive TB patients in selected districts of Karakalpakstan (Uzbekistan) and Dashoguz (Turkmenistan). High levels of MDR-TB were found in both regions. In Karakalpakstan, 14 (13%) of 106 new patients were infected with MDR-TB; 43 (40%) of 107 previously treated patients were similarly infected. The proportions for Dashoguz were 4% (4/105 patients) and 18% (18/98 patients), respectively. Overall, 27% of patients with positive smear results whose infections were treated through the DOTS program in Karakalpakstan and 11% of similar patients in Dashoguz were infected with multidrug-resistant strains of TB on admission. These results show the need for concerted action by the international community to contain transmission and reduce the effects of MDR-TB.

MeSH Terms
Adolescent Adult Aged Anti-Bacterial Agents/pharmacology Antitubercular Agents/pharmacology Child Drug Resistance, Multiple, Bacterial Female Humans Male Microbial Sensitivity Tests Middle Aged Mycobacterium tuberculosis/drug effects,isolation & purification Sputum/microbiology Tuberculosis, Multidrug-Resistant/epidemiology,microbiology Turkmenistan/epidemiology Uzbekistan/epidemiology
Chemicals
Anti-Bacterial Agents Antitubercular Agents
Authors & Affiliations
9 authors, click to expand affiliations / ORCID
Cox Helen Suzanne
Médecins Sans Frontières Aral Sea Area Programme, Uzbekistan and Turkmenistan, Tashkent, Uzbekistan. [email protected]
Orozco Juan Daniel
Male Roy
Ruesch-Gerdes Sabine
Falzon Dennis
Small Ian
Doshetov Darebay
Kebede Yared
Aziz Mohammed
References (10)
10 references, click to expand
  1. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries.
    JAMA. 2000 May 17;283(19):2537-45 PMID: 10815117
  2. Clinical outcomes of Estonian patients with primary multidrug-resistant versus drug-susceptible tuberculosis.
    Clin Infect Dis. 2001 Feb 1;32(3):373-80 PMID: 11170944
  3. Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance.
    N Engl J Med. 2001 Apr 26;344(17):1294-303 PMID: 11320389
  4. Acting on an environmental health disaster: the case of the Aral Sea.
    Environ Health Perspect. 2001 Jun;109(6):547-9 PMID: 11445505
  5. Inadequacy of the current WHO re-treatment regimen in a central Siberian prison: treatment failure and MDR-TB.
    Int J Tuberc Lung Dis. 1999 May;3(5):451-3 PMID: 10331736
  6. The nationwide tuberculosis drug resistance survey in Mongolia, 1999.
    Int J Tuberc Lung Dis. 2002 Apr;6(4):289-94 PMID: 11936736
  7. Drug resistance of Mycobacterium tuberculosis strains isolated from patients with pulmonary tuberculosis in Archangels, Russia.
    Int J Tuberc Lung Dis. 2002 May;6(5):406-14 PMID: 12019916
  8. Health sector reform in the former Soviet Republics of Central Asia.
    Int J Health Plann Manage. 1998 Apr-Jun;13(2):131-47 PMID: 10185505
  9. The dilemma of MDR-TB in the global era.
    Int J Tuberc Lung Dis. 1998 Nov;2(11):869-76 PMID: 9848606
  10. The burden of drug-resistant tuberculosis and mechanisms for its control.
    Ann N Y Acad Sci. 2001 Dec;953:88-97 PMID: 11795426
Article Info
Journal
Emerging infectious diseases
Abbr.
Emerg Infect Dis
ISSN
1080-6040
Published
2004-05-00
Pages
865-72
Language
English
Region
United States
NLM ID
9508155
PMCID
PMC3323206
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]